Literature DB >> 10964850

Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents.

S G Siris1.   

Abstract

OBJECTIVE: The author sought to provide a contemporary understanding of depression in schizophrenia and promote a treatment orientation.
METHOD: Computer and library-based resources were used to review the literature on depression in schizophrenia.
RESULTS: Despite multiple definitions of "depression," a substantial rate of depression has consistently been found in patients with schizophrenia. A differential diagnosis can be used to advance the understanding and treatment of depression in schizophrenia, and changes in response to the advent of atypical antipsychotic agents can be understood in the context of this differential diagnosis paradigm.
CONCLUSIONS: Depression is an important co-occurring syndrome in schizophrenia. In at least some schizophrenic patients, the stress-vulnerability model has potential as an integrating concept concerning the relationship between depression and psychosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10964850     DOI: 10.1176/appi.ajp.157.9.1379

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  61 in total

Review 1.  Elderly patients with schizophrenia and depression: diagnosis and treatment.

Authors:  Kandi Felmet; Sidney Zisook; John W Kasckow
Journal:  Clin Schizophr Relat Psychoses       Date:  2011-01

2.  Evaluation of Myo-Inositol as a Potential Biomarker for Depression in Schizophrenia.

Authors:  Joshua Chiappelli; Laura M Rowland; S Andrea Wijtenburg; Florian Muellerklein; Malle Tagamets; Robert P McMahon; Frank Gaston; Peter Kochunov; L Elliot Hong
Journal:  Neuropsychopharmacology       Date:  2015-02-27       Impact factor: 7.853

Review 3.  Measurement of functional capacity: a new approach to understanding functional differences and real-world behavioral adaptation in those with mental illness.

Authors:  Thomas L Patterson; Brent T Mausbach
Journal:  Annu Rev Clin Psychol       Date:  2010       Impact factor: 18.561

4.  Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis.

Authors:  Shaun M Eack; Christina E Newhill
Journal:  Schizophr Bull       Date:  2007-01-04       Impact factor: 9.306

5.  The revolving door phenomenon in psychiatry: comparing low-frequency and high-frequency users of psychiatric inpatient services in a developing country.

Authors:  Ulla A Botha; Liezl Koen; John A Joska; John S Parker; Neil Horn; Linda M Hering; Piet P Oosthuizen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-06-18       Impact factor: 4.328

Review 6.  The complement system in schizophrenia.

Authors:  Karine R Mayilyan; Daniel R Weinberger; Robert B Sim
Journal:  Drug News Perspect       Date:  2008-05

7.  GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.

Authors:  Ajaykumar N Sharma; Sagar S Ligade; Jay N Sharma; Praveen Shukla; Khalid M Elased; James B Lucot
Journal:  Metab Brain Dis       Date:  2014-07-15       Impact factor: 3.584

8.  Reliability and validity of the Calgary Depression Scale for Schizophrenia (CDSS) in youth at clinical high risk for psychosis.

Authors:  Jean Addington; Hely Shah; Lu Liu; Donald Addington
Journal:  Schizophr Res       Date:  2014-01-16       Impact factor: 4.939

Review 9.  Postpsychotic depression in schizophrenia patients.

Authors:  Christian G Kohler; Elise A Lallart
Journal:  Curr Psychiatry Rep       Date:  2002-08       Impact factor: 5.285

10.  Network analysis of auditory hallucinations in nonpsychotic individuals.

Authors:  Remko van Lutterveld; Kelly M J Diederen; Willem M Otte; Iris E Sommer
Journal:  Hum Brain Mapp       Date:  2013-02-21       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.